HTB
-
Featured
HTB May 2022 (2 May 2022)
2 May 2022. Related: Editorial.
-
Featured
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals, CROI 28 (virtual) 2021.
-
Featured
In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV
14 October 2020. Related: In memory.
-
Seven cases of monkeypox virus in the UK from 2018 to 2021
25 May 2022. Related: Early access, Coinfections and complications.
-
Risk of monkeypox becoming endemic in Europe: ECDC assessment
23 May 2022. Related: Early access, Coinfections and complications.
-
Monkeypox cases in gay men in the UK: BHIVA and ECDC rapid statements
19 May 2022. Related: Early access, Coinfections and complications.
-
Implications of SARS-CoV-2 in gut tissue for transmission of COVID-19 and long COVID
19 May 2022. Related: Early access, Coinfections and complications, COVID-19.
-
Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published
12 May 2022. Related: Early access, Antiretrovirals.
-
Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers
5 May 2022. Related: Other news.
-
Sending unused meds to Ukraine: emergency appeal
2 May 2022. Related: Editorial.
-
Organisations to support Ukraine
2 May 2022. Related: Editorial.
-
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
2 May 2022. Related: Conference reports, Conference index, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Other COVID-19 studies
2 May 2022. Related: Conference reports, Coinfections and complications, COVID-19.
-
FDA approves dispersible dolutegravir/abacavir/3TC for children
2 May 2022. Related: Antiretrovirals.
-
Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits
2 May 2022. Related: Antiretrovirals, Treatment access.
-
Asymptomatic COVID-19 is common in people living with HIV
2 May 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19.
-
Longest COVID-19 infection lasted 505 days in an immunocompromised person in London
2 May 2022. Related: Coinfections and complications, COVID-19: HIV and COVID-19 coinfection, COVID-19: pathogenesis, COVID-19.
-
Herd immunity unlikely to control COVID-19: opinion article from US NIAID
2 May 2022. Related: Coinfections and complications, COVID-19: transmission & prevention, COVID-19.
-
The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19
2 May 2022. Related: Coinfections and complications, COVID-19: complications, COVID-19.
-
Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms
2 May 2022. Related: Coinfections and complications, COVID-19: complications, COVID-19.
-
Two new platform vaccines against COVID-19 report phase 3 results
2 May 2022. Related: Coinfections and complications, Other news, COVID-19: vaccine research, COVID-19.
-
A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton
2 May 2022. Related: HIV prevention and transmission.
-
Zimbabwe decriminalises HIV transmission
2 May 2022. Related: HIV prevention and transmission, Other news.
-
Community webinar series on HIV cure-related cell and gene therapy
2 May 2022. Related: Cure research.
-
HTB: no. 5 (2 May 2022) PDF downloads
2 May 2022. Related: PDFs.
-
Future meetings and webinars 2022
2 May 2022. Related: Future meetings.
-
HTB April 2022 (1 April 2022)
1 April 2022. Related: Editorial.
-
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
1 April 2022. Related: Conference reports, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Webcasts now online and open access
1 April 2022. Related: Conference reports, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
-
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART
1 April 2022. Related: Conference reports, Coinfections and complications, CROI 29 (Retrovirus) 2022.
-
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Summary of 14 key studies on HIV and liver disease
1 April 2022. Related: Conference reports, Hepatitis coinfection.
-
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
1 April 2022. Related: Conference reports, Cure research.
-
US FDA removes need for oral lead-in with long-acting cabotegravir/rilpivirine injections: indication expanded to adolescents
1 April 2022. Related: Antiretrovirals.
-
HIV vaccine study using mRNA technology starts in the US
1 April 2022. Related: HIV prevention and transmission.
-
South Africa approves dapivirine vaginal ring for HIV prevention
1 April 2022. Related: HIV prevention and transmission.
-
BHIVA statement on fourth vaccine dose for people living with HIV in the UK
1 April 2022. Related: COVID-19: HIV and COVID-19 coinfection.
-
Temporary protection against omicron needs mRNA booster: limited data for those at highest risk
1 April 2022. Related: COVID-19: vaccine research, COVID-19.
-
HTB: no. 4 (1 April 2022) PDF downloads
1 April 2022. Related: PDFs.
-
Efficacy of mRNA vaccines in people with HIV or solid transplant recipients
8 March 2022. Related: COVID-19: vaccine research, COVID-19.
-
HTB March 2022 (1 March 2022)
1 March 2022. Related: Editorial.
-
EACS statement on the war in Ukraine
1 March 2022. Related: Editorial, Special reports.
-
Organisations to support the crisis in Ukraine
1 March 2022. Related: Editorial, Special reports.
-
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports, Conference index, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.
-
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals, CROI 29 (Retrovirus) 2022.